Indeed, current clinical trials are based on a combination of cGAS–STING pathway agonists with immune checkpoint inhibitors, such as pembrolizumab, ipilimumab, and nivolumab, for cancer immunotherapy. The gene discussed is CGAS; the disease is cancer.